Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is hosting a Virtual Fireside Chat on April 18, 2023, at 1:30 PM EDT, focused on ROR1 CAR-T Cell Therapy for hematological malignancies and solid tumors. Moderated by Oppenheimer's Hartaj Singh, the discussion features key opinion leaders, including Dr. Michael Wang and Dr. Angela Shen, alongside Oncternal's CEO, Dr. James Breitmeyer. This event will highlight Oncternal's investigational CAR-T therapy, ONCT-808, which targets ROR1 and demonstrates preclinical success against several cancers. The company is advancing its development pipeline for treatments addressing critical unmet medical needs in oncology, particularly in aggressive B-cell lymphoma and prostate cancer.
Oncternal Therapeutics announced the closure of its zilovertamab Phase 3 study (ZILO-301) and Phase 1/2 study (CIRM-0001) due to the evolving market for BTK inhibitors. This strategic shift aims to extend the company’s cash runway into 2025, supporting further clinical development of ONCT-808 and ONCT-534. ONCT-808, targeting aggressive lymphomas, and ONCT-534, a novel AR inhibitor for mCRPC, are set to yield initial clinical data by late 2023 and mid-2024, respectively. The company's cash and equivalents are reported at $54.3 million, supporting operations through 2025. A webcast with management is scheduled for today at 5:00 PM ET.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the approval of an inducement award to new employee Erik S. Nelson as Head of IT. The award includes an option to purchase 64,900 shares of common stock, vesting over four years. This decision aligns with Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting talent. The option price will match the stock's closing price on the grant date, April 3, 2023. The plan has been approved by independent directors per Nasdaq rules. Oncternal focuses on innovative oncology therapies targeting critical unmet medical needs in cancer treatment.